Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Lineage Cell Therapeutics (LCTX) Receivables - Other (2016 - 2025)

Lineage Cell Therapeutics' Receivables - Other history spans 13 years, with the latest figure at $671000.0 for Q4 2025.

  • For Q4 2025, Receivables - Other changed N/A year-over-year to $671000.0; the TTM value through Dec 2025 reached $671000.0, changed N/A, while the annual FY2025 figure was $671000.0, N/A changed from the prior year.
  • Receivables - Other reached $671000.0 in Q4 2025 per LCTX's latest filing, up from $549000.0 in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $671000.0 in Q4 2025 to a low of $200000.0 in Q2 2022.
  • Average Receivables - Other over 3 years is $513500.0, with a median of $547000.0 recorded in 2022.
  • The largest YoY upside for Receivables - Other was 8.6% in 2022 against a maximum downside of 8.6% in 2022.
  • A 3-year view of Receivables - Other shows it stood at $535000.0 in 2021, then rose by 8.6% to $581000.0 in 2022, then rose by 15.49% to $671000.0 in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Receivables - Other are $671000.0 (Q4 2025), $549000.0 (Q3 2025), and $581000.0 (Q4 2022).